Related Articles
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827
EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature
The PLC-PKC cascade is required for IL-1β-dependent Erk and Akt activation: their role in proliferation
Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑naïve non‑small cell lung carcinoma